10x Genomics CEO Sold $2M Before 7% Rally
10x Genomics shares rallied 7.42% on September 24 on reports of an AI partnership and legal win, but CEO Serge Saxonov sold $2 million in shares two days earlier. Insiders have sold $12.24 million ove
10x Genomics CEO Sold $2M Two Days Before 7% Rally
NEW YORK, September 28 —
Two trading days before 10x Genomics, Inc. (TXG) shares surged 7.42% on reports of an AI partnership and a legal win, CEO Serge Saxonov sold 25,000 shares for $2.03 million. Neither catalyst has appeared in an SEC filing. At $89.44, TXG now trades 52% above the $58.80 analyst consensus on 813x forward earnings.
- CEO Saxonov sold 25,000 shares Sept. 22 for $2.03M; shares rallied 7.42% two days later on unconfirmed news.
- TXG at $89.44, 52% above the $58.80 analyst consensus, on 813x forward earnings; trailing revenue fell 12.7%.
- $12.24M in net insider sales over 90 days with zero purchases; short interest is 18.8% of the float.
Nobody Bought
Saxonov's September 22 sale was not isolated. Per SEC filings, CFO Adam Taich sold 46,388 shares on September 9 at $63.68, $65.26 for approximately $3.0 million, with a single block of 31,428 shares at $64.31 accounting for $2.02 million. Director John Stuelpnagel separately sold 40,000 shares across August and September for roughly $2.4 million. The 90-day tally across the CEO, CFO, director, and other insiders reaches $12.24 million in open-market sales with zero purchases, all selling, none buying, before the rally. Cost discipline explains four straight EPS beats; it does not explain why every insider with open-market activity sold.
Priced for Transformation
10x Genomics builds instruments, consumables, and software for single-cell and spatial biology. Chromium handles single-cell RNA sequencing, Visium covers spatial transcriptomics, and Xenium performs in situ RNA detection across fresh or fixed tissue sections. Four consecutive EPS beats, the most recent at 240% above consensus, reflect cost discipline: trailing revenue is $620 million, down 12.7%, and trailing EPS is -$0.59. An 813x forward multiple, visible through any P/E calculator at these figures, prices the AI and legal catalysts as transformational. The $550 million cash balance and positive free cash flow give the company runway; they do not bridge the gap to an $11.65 billion market cap.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TXG | $11.6B | n/a | +655.8% |
| TWST | $12.1B | n/a | +577.1% |
| BEAM | $2.5B | n/a | +1.5% |
| PACB | $547M | n/a | +29.6% |
| VCYT | $3.7B | 23.9x | +35.2% |
| GH | $23.9B | n/a | +185.9% |
The 8-K That Settles It
The thesis resolves on the next SEC disclosure. Material agreements, AI partnerships and significant licensing deals among them, require a Form 8-K. No such filing has appeared since news outlets attributed TXG's September 24 rally to those catalysts. If a confirmed partnership with named counterparties and revenue implications files, the bear case weakens materially; if nothing files, the rally was headline-driven and 18.8% short interest becomes a live catalyst. Revenue inflection, not EPS beats from cost cuts, is the metric that changes the valuation argument. Run the free TXG deep-dive → before the next filing drops.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did the 10x Genomics CEO sell shares before the rally?
CEO Serge Saxonov sold 25,000 shares for $2.03 million on September 22, two days before the stock rallied 7.42% on reports of an AI partnership and legal win. The sale occurred before any of these catalysts appeared in SEC filings.
Is 10x Genomics overvalued at current prices?
The stock trades at $89.44, which is 52% above the $58.80 analyst consensus, on an 813x forward earnings multiple. Trailing revenue fell 12.7% and the company has trailing EPS of negative $0.59, making the current valuation depend almost entirely on unconfirmed AI partnership growth.
Did other insiders at 10x Genomics sell shares?
Yes. CFO Adam Taich sold 46,388 shares in September for approximately $3.0 million, and Director John Stuelpnagel sold 40,000 shares across August and September for roughly $2.4 million. Over 90 days, insiders sold $12.24 million with zero purchases.
What products does 10x Genomics manufacture?
10x Genomics builds instruments, consumables, and software for single-cell and spatial biology, including Chromium for single-cell RNA sequencing, Visium for spatial transcriptomics, and Xenium for in situ RNA detection.
What SEC filing is expected after the rally?
Material agreements, including AI partnerships and significant licensing deals, require a Form 8-K filing. The absence of any SEC filing since the September 24 rally on reports of these catalysts is the most informative data point currently available.
CEO Serge Saxonov sold 25,000 TXG shares for approximately $2.03 million on September 22, two trading days before the stock jumped 7.42% on news reports of an AI partnership and a legal win that no SEC filing has confirmed. At $89.44, shares now trade approximately 52% above the $58.80 analyst consensus price target while trailing revenue is down 12.7%.